These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 23614365)

  • 1. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
    Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
    Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of oncotype DX recurrence score in the management of breast cancer cases.
    Nguyen MT; Stessin A; Nagar H; D'Alfonso TM; Chen Z; Cigler T; Hayes MK; Shin SJ
    Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
    Lee JJ; Shen J
    Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
    Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
    Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
    Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
    Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
    Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
    Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
    Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM; Ebel JJ; Zhao W; Zynger DL
    Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
    Rayhanabad JA; Difronzo LA; Haigh PI; Romero L
    Am Surg; 2008 Oct; 74(10):887-90. PubMed ID: 18942607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.